What blood stem cells are and why they matter
Blood stem cells, also called hematopoietic stem cells or HSCs, are the cells in bone marrow and blood that give rise to every type of blood cell your body needs, including red blood cells, white blood cells, and platelets. Unlike many specialized cells, blood stem cells can both self-renew and transform into multiple blood cell types, enabling lifelong blood formation and recovery after injury or treatment. These versatile cells are foundational to treatments for blood cancers, immune disorders, and certain inherited blood conditions. This guide explains how blood stem cells work, where they come from, how they are collected and used therapeutically, and what the evidence shows about their long-term function and safety.
Types and locations of blood stem cells
Blood stem cells exist in several locations in the body and differ by developmental stage and function. The main types and their typical sources are summarized below.
| Stem cell type or source | Key traits and timing | Primary source or context |
|---|---|---|
| Embryonic stem cells (pluripotent) | Can form all cell types, including blood; present days 3–7 after fertilization | Early embryo (blastocyst) |
| Fetal liver and spleen | Major blood cell production site mid-pregnancy | Developing fetus |
| Hematopoietic stem cells (HSCs) | Self-renew and make all mature blood cells; multipotent | Adult bone marrow, peripheral blood, umbilical cord blood |
| Mesenchymal stem cells (MSCs) | Support blood stem cells, can become bone, cartilage, fat | Bone marrow, fat tissue, umbilical cord tissue |
| Induced pluripotent stem cells (iPSCs) | Reprogrammed adult cells with pluripotent potential; experimental for blood diseases | Reprogrammed skin or blood cells |
Hematopoietic stem cells in adults
In children and adults, hematopoietic stem cells primarily reside in the bone marrow, especially in the pelvis, sternum, ribs, and vertebrae. A smaller pool circulates in the blood, and these cells can be found in umbilical cord blood. When needed, HSCs move from niches in the bone marrow into blood and tissues to replace dying or damaged cells. They are the starting material for treatments that restore blood and immune function after high-dose chemotherapy, radiation, or certain inherited disorders.
Peripheral blood stem cells vs. bone marrow stem cells
Peripheral blood stem cells (PBSCs) are HSCs that have been stimulated to leave the bone marrow and enter circulation, often using growth-factor drugs. Collecting PBSCs via apheresis is common for adult donors and patients, because it is usually faster and involves less discomfort than bone marrow extraction. By contrast, bone marrow collection involves filtering liquid marrow from the pelvis under anesthesia. Cord blood stem cells are collected after birth from the umbilical cord and placenta and stored in public and family banks for potential future use. Each source has tradeoffs in cell dose, collection time, and patient suitability.
How blood stem cells work in the body
Blood stem cells maintain blood and immune cell production throughout life through a balance of self-renewal and differentiation. Mature blood cells have limited lifespan and are continuously consumed by the immune system or routine bodily processes. Blood stem cells periodically replenish these populations. Key steps include quiescence (a resting state that protects the stem cell pool), activation in response to injury or infection, and careful gene regulation that ensures the right mix of blood cell types. Disruptions in this system can lead to anemia, increased infection risk, or bleeding problems.
Stages from stem cell to mature blood cell
- Hematopoietic stem cell (self-renewing, multipotent).
- Early progenitor cells (proliferate and begin lineage commitment).
- Late progenitor and precursor cells (more restricted, still expanding).
- Immature blast cells (less proliferative, more specialized).
- Mature red blood cells, neutrophils, platelets, and lymphocytes (perform oxygen transport, immunity, and clotting).
At each stage, transcription factors, signaling proteins, and the surrounding microenvironment guide the cells toward their final roles. Understanding these pathways has made it possible to culture, expand, and in some cases genetically modify blood stem cells for therapy.
Clinical uses and evidence-based applications
Blood stem cells are used most commonly in transplantation for patients whose own blood or immune system is damaged or cancerous. Transplants replace diseased marrow with healthy stem cells that produce normal blood and immune cells. The approach is well established for some conditions and still investigational for others, depending on evidence and risk–benefit profiles.
Conditions commonly treated with blood stem cell transplantation
- Acute leukemias (AML and ALL) and chronic leukemias (CML)
- Lymphomas (Hodgkin and non-Hodgkin)
- Multiple myeloma
- Aplastic anemia and certain inherited bone marrow failure syndromes
- Some metabolic and immune disorders that affect blood and immune cells
Transplant types
- Autologous transplant: Uses the patient’s own stem cells, collected and stored before high-dose therapy; best for selected cancers where the disease is not in the marrow.
- Allogeneic transplant: Uses stem cells from a matched donor (sibling, unrelated volunteer, or cord blood); includes immune effects (graft-versus-tumor and graft-versus-host disease) that can influence outcomes.
- Umbilical cord blood transplant: Useful when a matched adult donor is not available; slower immune and blood recovery but lower risk of graft-versus-host disease.
Collection, storage, and safety considerations
How blood stem cells are collected depends on the source and clinical plan. Bone marrow harvest is done under anesthesia, involves filtering marrow from the pelvis, and typically requires a short hospital stay. Peripheral blood stem cell collection uses a machine that separates white blood cells and stem cells from blood after donor or patient receives mobilization drugs; the remaining blood components are returned. Cord blood is collected after the cord is clamped and does not harm the newborn.
Before transplantation, patients undergo conditioning (chemotherapy and/or radiation) to clear diseased marrow and suppress the immune system. This makes space for the new cells but also carries risks, including infection, bleeding, and organ stress. After infusion, clinicians monitor blood counts, immune recovery, and signs of complications such as graft failure or graft-versus-host disease. Long-term follow-up tracks survival, late effects, and whether the new blood and immune systems remain stable.
Practical considerations and current evidence
Success after blood stem cell transplantation depends on many factors, including disease type, stage, patient age, donor match quality, and prior treatments. Younger patients and those with matched sibling donors often have better outcomes, but outcomes vary widely. Cord blood units with higher cell doses are associated with faster engraftment and reduced infection risk. Ongoing research continues to refine conditioning regimens, manage graft-versus-host disease, and expand the use of haploidentical (half-matched) donors.
For non-transplant uses of blood stem cells—such as gene therapy or ex vivo expansion—the field is evolving. Some approaches modify a patient’s own cells for rare genetic defects or immune deficiencies; these are typically offered within clinical trials due to limited long-term data. Public registries and cord blood banks increase availability, especially for patients without a matched family donor.